Teriflunomide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1032 publications

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: May 05, 2026

Molecular Target Discovery and Systemic Mechanism Analysis of Teriflunomide for Dry Eye Disease.

Molecular Target Discovery and Systemic Mechanism Analysis of Teriflunomide for Dry Eye Disease.

Journal: Current issues in molecular biology

Published: April 23, 2026

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Journal: Expert opinion on pharmacotherapy

Published: April 21, 2026

The Role of Pharmacogenetics in the Effectiveness of Rheumatoid Arthritis Treatment with Leflunomide.

The Role of Pharmacogenetics in the Effectiveness of Rheumatoid Arthritis Treatment with Leflunomide.

Journal: Genes

Published: April 13, 2026

Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders.

Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders.

Journal: Continuum (Minneapolis, Minn.)

Published: April 02, 2026

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

Journal: Journal of neurology

Published: March 14, 2026

Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.

Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: March 10, 2026

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: February 20, 2026

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Journal: JAMA neurology

Published: February 16, 2026

Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis.

Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis.

Journal: Neurology and therapy

Published: January 27, 2026

LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis.

LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis.

Journal: Biochemistry and biophysics reports

Published: January 19, 2026

Showing 1-12 of 1,032

Last Updated: 06/30/2026